House GOP to FDA: Deliver documents on meningitis crisis
WASHINGTON — Republicans on a congressional panel investigating a deadly meningitis outbreak linked to tainted drugs have told the nation's top drug regulator not to expect new authority to prevent more problems until the agency hands over documents about its role in the crisis.
As the number of meningitis cases edged toward the 500 mark, the House of Representatives Energy and Commerce Committee's Republican majority staff released on Monday a letter that gave the Food and Drug Administration until the end of November to comply with a document request first made in mid-October.
“We need these documents to identify any possible weaknesses in FDA's regulatory system that can be immediately corrected administratively or legislatively,” said the letter, dated Nov. 16 and addressed to FDA Commissioner Margaret Hamburg by four Republicans.
“This committee has a long history of thoroughly and deliberatively investigating problems and offering solutions. We cannot and will not be in a position to do so in this case until we have a full accounting,” the letter said.
FDA officials had no comment.
The regulatory agency has asked lawmakers to clarify its authority to oversee large-scale drug compounders such as Massachusetts-based New England Compounding Center, the maker of epidural steroid injections that have been linked to a fungal meningitis outbreak that has now killed 33 people in 19 states.
Drug compounding is a longstanding practice in which pharmacists alter or recombine existing drugs to meet the special needs of specific patients. Some compounders have evolved into large-scale producers that experts say should be subject to FDA regulation.
State pharmacy boards are primarily responsible for oversight. FDA officials say their authority to oversee compounders has been challenged regularly in federal court, leading to conflicting rulings in different parts of the country.
A handful of House Democrats have called for congressional action to bring clarity to the situation before year end. But at a committee hearing on Nov. 14, several Republicans charged that FDA already had the authority to avoid the outbreak but failed to, despite repeated problems at NECC.
On Oct. 17 the committee submitted a bipartisan request for FDA documents relating to the outbreak including its dealings with NECC and the Massachusetts pharmacy board that was the primary regulator for NECC.
The latest letter to FDA contained no Democratic signatures.
Republicans said a similar request to Massachusetts health authorities produced thousands of internal state emails.
“FDA has provided the committee with zero. In fact, when asked by committee staff on Nov. 16, FDA staff stated that they had not even begun to search for responsive emails,” their letter said.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Social Security’s $300M IT project doesn’t work
- Medical pot could bring Fla. tax revenue windfall
- U.S. knew Islamist militants planned offensive in Iraq, lawmakers told
- Obamacare enrollees strain Medicaid in Oregon
- Lawmakers, allies waver on planned troop pullout from Afghanistan
- Can Georgia GOP ‘outsider’ Perdue best Democrats’ Nunn?
- Fire season expected to accelerate
- Man told transit police the Boston Marathon bomber ‘was my best friend’
- Massachusetts teen held in teacher’s slaying accused assaulting detention center worker
- Ariz. inmate’s execution apparently botched